Showing posts with label treatment related second primary. Show all posts
Showing posts with label treatment related second primary. Show all posts
Monday, January 09, 2012
abstract: Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: An epidemiological analysis
CONCLUSION: Development of t-AML is a rare but lethal event among EOC patients, and its incidence has decreased significantly since the use of platinum/taxane-based chemotherapy became the standard of care.
Subscribe to:
Posts
(
Atom
)
